Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY P2 Bracelet-1 trial showed pelareorep as sole agent

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 19, 2023 7:48pm

88 Views

Post# 35692095

RE:RE:ONCY P2 Bracelet-1 trial showed pelareorep as sole agent

The global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022

And with the potential use of pelareorep in combination with a checkpoint and CDK4/6 or PARP inhibitor, in 2L HR+/HER2- advanced or metastatic breast cancer, in which optimal second-line therapy for hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer is yet to be established, ONCYs acquisition valuation still remains in the multi-Billions.

Nothing has changed for ONCY other than pelareorep will be used as second line treatment in HR+/HER2- (or HER2 low) advanced or metastatic breast cancer , when combined with a CPI, plus possibly a CDK4/6 and PARP inhibitor, on the expected treatment relapes/failures/adverse effects on the anti-body drug conjugate (ADC) Enhertu.

https://www.enhertu.com/en/gastric/risks-and-side-effects

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec